IL315809A - Mglur5 modulating compounds, compositions, and methods of use - Google Patents

Mglur5 modulating compounds, compositions, and methods of use

Info

Publication number
IL315809A
IL315809A IL315809A IL31580924A IL315809A IL 315809 A IL315809 A IL 315809A IL 315809 A IL315809 A IL 315809A IL 31580924 A IL31580924 A IL 31580924A IL 315809 A IL315809 A IL 315809A
Authority
IL
Israel
Prior art keywords
compound
degrees
solvate
solvate form
xrpd pattern
Prior art date
Application number
IL315809A
Other languages
English (en)
Hebrew (he)
Original Assignee
Allyx Therapeutics Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allyx Therapeutics Inc, Univ Yale filed Critical Allyx Therapeutics Inc
Publication of IL315809A publication Critical patent/IL315809A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL315809A 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use IL315809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263322446P 2022-03-22 2022-03-22
PCT/US2023/015966 WO2023183428A1 (en) 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use

Publications (1)

Publication Number Publication Date
IL315809A true IL315809A (en) 2024-11-01

Family

ID=88101942

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315809A IL315809A (en) 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use

Country Status (9)

Country Link
US (1) US20250230149A1 (https=)
EP (1) EP4496572A4 (https=)
JP (1) JP2025509988A (https=)
KR (1) KR20250008042A (https=)
CN (1) CN119300827A (https=)
AU (1) AU2023238896A1 (https=)
CA (1) CA3246263A1 (https=)
IL (1) IL315809A (https=)
WO (1) WO2023183428A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080252A1 (en) * 2023-10-13 2025-04-17 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) * 2024-03-06 2025-09-12 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691821B2 (en) * 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5

Also Published As

Publication number Publication date
WO2023183428A8 (en) 2023-12-14
AU2023238896A1 (en) 2024-10-03
KR20250008042A (ko) 2025-01-14
CA3246263A1 (en) 2023-09-28
EP4496572A1 (en) 2025-01-29
US20250230149A1 (en) 2025-07-17
CN119300827A (zh) 2025-01-10
JP2025509988A (ja) 2025-04-11
EP4496572A4 (en) 2026-03-11
WO2023183428A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
US20250230149A1 (en) Mglur5 modulating compounds, compositions, and methods of use
EP2170322B1 (en) METHODS OF MODIFYING AMYLOID ß OLIGOMERS USING NON-PEPTIDIC COMPOUNDS
KR20150139830A (ko) 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법
EP2173340A1 (en) Methods of enhancing cognitive function using non-peptidic compounds
US20260062418A1 (en) Solid forms of posiphen d-tartrate
TW201513859A (zh) 瞼板腺功能障礙之治療劑
US20180000792A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
US20240189277A1 (en) Ophthalmic formulations for sustained neuroprotection
EP1481007B1 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
CN113330007A (zh) 尼拉帕利游离碱的晶体形式
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
JP7048629B2 (ja) 医薬組成物およびその使用
UA130011C2 (uk) Спосіб лікування нейродегенеративних розладів
AU2023468841A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025080252A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
US20170252403A1 (en) Methods and compositions for treating retinal disorders
WO2025188734A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
KR20140146036A (ko) 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
KR102065236B1 (ko) 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법
WO2024027752A1 (zh) 包含杂环化合物的药物组合物及其制备方法和应用
WO2022169642A1 (en) Okn-007 as a therapeutic agent for neurodegenerative diseases
TW202547500A (zh) 用於抑制werner氏症候群atp依賴性解旋酶之化合物及方法